Drug Database
Back to search

Belgium· BE-AMP-SAM478960-00

Keytruda 50 mg

A pembrolizumab product containing pembrolizumab, registered in Belgium by Merck Sharp & Dohme. The same ATC class is registered in 2 of our 19 countries.

ATC L01XC18

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedKeytruda 50 mgATCL01XC18REGISTER NO.BE-AMP-SAM478960-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about pembrolizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Pembrolizumab is registered in 2 of 19 countries.

Countries holding a registration under ATC L01XC18 (pembrolizumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 1 of them publish a price we can compare per daily dose
Search pembrolizumab products by name

Pembrolizumab · ATC L01XC18

2 / 19 countries

  • Belgiumprice
  • Ireland
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Pembrolizumab
Manufacturer
Merck Sharp & Dohme
Country
Belgium (BE)
ATC code
L01XC18
ATC class
Pembrolizumab
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    3320116
  • be_apb
    7715238

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

20 interactions on record for pembrolizumab.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check pembrolizumab against other medicinesHow interaction checks work

Pembrolizumab · interactions on record

20 records

  • 3 severe
  • 17 moderate

Most severe, free to view

  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • PomalidomideL04AX06severe
  • PrednisoloneA07EA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pembrolizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pembrolizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Keytruda
  • Liechtenstein · Keytruda
  • Norway · Keytruda

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c08d8851-db63-4581-9bf4-cb8d58f513a7
GET /v1/drugs/c08d8851-db63-4581-9bf4-cb8d58f513a7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder for concentrate for solution for infusion",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Keytruda 50 mg",
  "name_fr": "Keytruda 50 mg",
  "name_nl": "Keytruda 50 mg",
  "amp_code": "SAM478960-00",
  "strengths": [
    "50.0000",
    "50.0000"
  ],
  "pack_count": 2,
  "substances": [
    "Pembrolizumab"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Pembrolizumab",
  "authorisation_numbers": [
    "EU/1/15/1024/001"
  ]
}
API referenceMCP serverPlans

See everything about pembrolizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console